Navigation Links
Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
Date:4/7/2010

Sullivan played a vital role in Merrimack's acquisition of Hermes Biosciences and partnership with sanofi-aventis

Cambridge, MA (PRWEB) April 7, 2010 -- Merrimack Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the discovery and development of novel treatments for cancer and inflammation, today announced that William Sullivan has been promoted to Vice President of Finance.

“Bill has led Merrimack’s finance and accounting efforts and played a vital role in both our acquisition of Hermes Biosciences and the completion of our partnership with sanofi-aventis,” said Robert Mulroy, President and Chief Executive Officer of Merrimack Pharmaceuticals. “His past experience coupled with the work he has done at Merrimack gives our leadership team and Board of Directors full confidence that Bill is the right choice to successfully direct the Company’s financial strategy.”

In his new position, Sullivan, will continue to lead Merrimack’s finance department to ensure the Company is prepared for growth and future financings. In addition to his previous role, Sullivan now has full responsibility for the Company’s daily financial and legal operations.

Bill Sullivan brings broad experience to the role. He has established and managed finance departments and worked in public and private corporate accounting. He holds a Bachelor’s degree from Williams College, a Master’s degree in Business Administration (MBA) and a Master’s degree in Accounting from Northeastern University’s Graduate School of Professional Accounting. He is a Certified Public Accountant (CPA).

About Merrimack
Merrimack is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and discovery stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology, and computing to enable mechanism-based, model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit http://www.merrimackpharma.com.

Contact:    
Kathleen Petrozzelli, Corporate Communications, 617-441-1043
Betsy Stevenson, RaymondStevenson Healthcare, 860-984-1424

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3841934.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
2. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
3. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
4. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
5. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
6. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
7. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
8. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
9. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
10. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
11. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces ... addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market ... hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. (NASDAQ: ... announces the filing of its 2016 Annual Report on Form 10-K ... Commission. ... 10-K is available in the Investor Relations section of the Company,s ... the SEC,s website at http://www.sec.gov . 2016 Year ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):